Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Temodex is an experimental localized chemotherapy formulation consisting of the alkylating agent temozolomide incorporated into a biodegradable polymer, often described as a hydrogel or powder for gelation. Developed by Grandeur Bio (Shijiazhuang Yuanjia Biotechnology) and originally originating from the Research Institute for Physical and Chemical Problems of the Belarusian State University, it is designed for the treatment of brain cancers, specifically glioblastoma multiforme. The product is intended for application directly into the resection cavity following surgical tumor removal. This approach aims to provide a high local concentration of temozolomide to eliminate residual tumor cells through sustained release, thereby enhancing therapeutic efficacy while minimizing the systemic toxicity typically associated with oral temozolomide administration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Temodex.